Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8644556 | 0.97 | TDP1 (0.62) | TDP1KMT2AMDM2CTDSP1MAPT | |
| Ethylene SCHEMBL6996408 | 0.85 | TDP1 (0.50) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL7001206 | 0.82 | TDP1 (0.44) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL7001209 | 0.82 | TDP1 (0.44) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL9042668 | 0.82 | TDP1 (0.44) | TDP1KMT2AMDM2CTDSP1CA9 | |
| Ethylene SCHEMBL6999766 | 0.82 | TDP1 (0.49) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL8644165 | 0.79 | TDP1 (0.68) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL8646533 | 0.79 | TDP1 (0.53) | TDP1KMT2AMDM2CTDSP1MEN1 | |
| Hydrochloric Acid SCHEMBL8643749 | 0.79 | TDP1 (0.67) | TDP1KMT2AMDM2CTDSP1MAPT | |
| SCHEMBL13633074 | 0.78 | TDP1 (0.68) | TDP1KMT2AMDM2CTDSP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0753514-A1 | ALKYLENEDIAMINE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | TDP1 3378/4885KMT2A 1497/4885MDM2 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.